OBJECTIVE. To evaluate the efficacy of a standardized regimen for decolonization of methicillin-resistant Staphylococcus aureus (MRSA) carriers and to identify factors influencing decolonization treatment failure. SETTING. University hospital with 750 beds and 27,000 admissions/year. PATIENTS. Of 94 consecutive hospitalized patients with MRSA colonization or infection, 32 were excluded because of spontaneous loss of MRSA, contraindications, death, or refusal to participate. In 62 patients, decolonization treatment was completed. At least 6 body sites were screened for MRSA (including by use of rectal swabs) before the start of treatment.
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In past decades, methicillin-resistant Staphylococcus aureus and outbreaks among injection drug abusers, prisoners, homeless (MRSA) has become the most important multidrug-resistant individuals, sports teams, and children in day care centers. 5, 6 pathogen worldwide, causing significant morbidity and increased Studies of surgical patients colonized with methicillinhealthcare costs.
1,2 MRSA colonization precedes MRSA infection, susceptible S. aureus have demonstrated that decolonization which occurs in 20%-60% of colonized patients in acute-care treatment-for example, with mupirocin-can reduce the infacilities and in 3%-15% of those in long-term-care facilities. 3 The cidence of subsequent infection. 7 In addition, most authorities rate of nosocomial transmission of MRSA in healthcare facilities recommend that MRSA carriers be decolonized in outbreak can be reduced by the use of strict infection-control measures, situations. such as establishment of MRSA surveillance; early identification MRSA decolonization may reduce the risk of MRSA infecof carriers; isolation of colonized or infected patients; use of bartion in individual carriers and could prevent MRSA spread in rier precautions, such as use of gloves, gowns, and masks, for pahealthcare facilities and in the community by eliminating a tient care; use of strict hand hygiene with alcohol-based hand reservoir for the organism. Several topical and systemic antirubs; and careful environmental cleaning in patient rooms. 3, 4 Remicrobial agents have been used for MRSA decolonization, cently, community-associated strains of MRSA have begun to with limited success rates. 811 However, most of the studies are spread in the community, causing intrafamily clusters of infection limited by the selection of patients (such as when patients with MRSA infection are excluded), small sample sizes, and methodological flaws. 8 Therefore, the effectiveness of MRSA decolonization is still controversial, and it is not routinely recommended.
The present study was performed to evaluate the efficacy of a standardized MRSA decolonization treatment regimen for MRSA-colonized and MRSA-infected patients and to identify factors influencing the failure of the decolonization program.
M E T H O D S Setting
The University Hospital Basel is a primary-and tertiary-care center with 750 beds and 27,000 admissions/year. Since 1993, data on all patients colonized or infected with MRSA have been prospectively collected by use of case report forms and entered into a database. The local prevalence of methicillin resistance among S. aureus isolates has remained low (less than 5%) during the past decade. 12 Screening for MRSA by analysis of nose and throat swab samples is routinely performed for patients who (1) are transferred from areas with MRSA endemicity, (2) have a history of MRSA colonization, (3) have a history of injection drug use, or (4) have been in contact with a known MRSA carrier.
Study Design and Definitions
We conducted a prospective cohort study from January 1, 2002, to April 30,2007 . All patients admitted to the University Hospital who were colonized or infected with MRSA were eligible for decolonization treatment. Patients who were unable or failed to attend follow-up visits were excluded from the analysis. For the purpose of the present study, MRSA colonization was defined as being present in any patient from whom MRSA was cultured from any body site (from routine screening or clinical specimens). MRSA infections were defined by use of the criteria of the Centers for Disease Control and Prevention. 13 In an adaptation of the Centers for Disease Control and Prevention definition, a case of MRSA colonization was defined as "community acquired" if the patient had (1) no history of MRSA colonization; (2) no history of hospitalization, surgery, or hemodialysis in the previous 12 months; and (3) an MRSA strain that was not epidemiologically linked to the hospital strains. A case was defined as "healthcare associated" if the patient (1) underwent hospitalization in an acute-care or longterm-care facility, hemodialysis, or any surgery in the previous 12 months and (2) had an MRSA strain that was epidemiologically not linked to the hospital strains. A case was defined as "nosocomial" if the patient had MRSA colonization diagnosed more than 48 hours after hospital admission, 30 days after an operation, or 1 year after implantation of persistent foreign body material (eg, a joint prosthesis).
Decolonization
Before initiation of decolonization treatment, all patients with MRSA colonization underwent standardized screening, using samples collected by use of polyester fiber-tipped swabs from the following body sites: the nose, throat, inguinal area, perineal area, rectum, vagina (in women), wounds, and insertion sites of catheters. In addition, urine culture for MRSA was performed for patients with urinary catheters or urinary-tract infection.
Decolonization treatment was offered to all patients. It consisted of a 5-day standard regimen of application of mupirocin ointment (Bactroban; GlaxoSmithKline) twice daily, oral rinsing with 0.2% chlorhexidine solution (Dentohexin; Streuli Pharma) 3 times daily, and daily body washing with 4% chlorhexidine soap (Lifoscrub; B. Braun). In addition, specific decolonization treatment was administered for urogenital and gastrointestinal colonization: for patients with MRSA colonization of the urine, cotrimoxazole (800/160 mg twice daily) was administered for 5 days, if the strain was susceptible. For gastrointestinal colonization (indicated by an MRSA-positive rectal swab sample), oral vancomycin (1 g twice daily) was administered for 5 days. Vaginal colonization was treated with a povidone-iodine ovula (Betadine; Mundipharma Medical Company) administered once daily for 5 days as a first choice or, alternatively, a hexetidine ovula (Vagi-Hex; Drossapharm) administered twice daily for 6 days or octenidine solution (Octenisept; Schiilke & Mayr) twice daily for 6 days for patients who did not tolerate or had contraindications for the use of a povidone-iodine ovula.
If a first cycle of decolonization treatment failed, the management of treatment was evaluated for potential obstacles to success-for example, noncompliance. Thereafter, a second cycle was started with the same regimen as described above. Systemic antibiotic treatment was recommended for patients whose conditions did not respond to 2 full cycles of decolonization treatment. Such patients were treated with fusidic acid (500 mg 3 times daily) and rifampin (450 mg twice daily) for 5 days. Other antibiotics were chosen on an individual basis for patients colonized with MRSA strains resistant to fusidic acid or rifampin.
MRSA decolonization was considered to be successful if there was no growth in 3 sets of surveillance cultures of samples (from the nose, throat, inguinal area, perianal area, rectum, vagina [in women], wounds, insertion sites, or urine [for patients with urinary-tract colonization]) obtained at least 2-3 days after completion of decolonization treatment at intervals of 2-3 days. After successful MRSA decolonization, follow-up cultures (of nose and throat samples) were performed at every subsequent hospital admission. All patients ever colonized with MRSA are labeled in the hospital mainframe system, and an alarm is sent to the department of hospital epidemiology within minutes after admission. 
Identification of MRSA and Molecular Typing
MRSA screening was performed by means of culture in a highly selective enrichment broth, as described elsewhere. 12 At the University Hospital Basel, each nonrepetitive clinical MRSA isolate has been typed by pulsed-field gel electrophoresis (PFGE) since 1993 and saved at -70°C. In addition, strains have been typed by polymerase chain reaction (PCR) 14 and, more recently, by spa typing. 15 For the present study, MRSA isolates were thawed from frozen storage and subcultured twice. DNA was extracted by use of the LC MagnaPure system (Roche Diagnostics), in accordance with the manufacturer's instructions. Genes for Panton-Valentine leukocidin (pvl); toxic shock syndrome toxin (tsst); exfoliative toxins A, B, and D (eta, etb, and etd); and methicillin resistance (tnecA) were detected by PCR, as described elsewhere. 1619 The polymorphic X region of the spa gene was amplified using primers spa-1113f and spa-1514r and sequenced as described elsewhere. 15 Sequences were analyzed by use of StaphType software, version 1.5.4, and SpaServer (both Ridom). 20 Analysis of clustering into spa clonal complexes (spaCCs) was done using default parameters. Susceptibility to mupirocin was determined by E-test (AB Biodisk) and interpreted according to the commonly used definition (minimum inhibitory concentration for low-level resistance, 4-256 tig/mL; minimum inhibitory concentration for high-level resistance, more than 512 ju-g/mL).
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Statistical Analysis
Data were analyzed with SPSS version 14.0.1 for Windows (SPSS). Kaplan-Meier curves were used to describe the probability of decolonization success; covariates were compared using the log rank test. P < .05 was considered to be significant.
R E S U L T S
During the study period, 94 cases of MRSA colonization or infection in hospitalized patients were identified, corresponding to prevalences of 0.1 cases per 100 patients discharged and 1.2 cases per 10,000 patient-days. Thirty-two cases were excluded from the analysis (Figure 1 ). For 11 patients, MRSA did not grow in screening cultures at the time when additional cultures were performed before decolonization was initiated, and all 11 patients had negative results for 3 sets of screening cultures at follow-up.
The most common sites of MRSA colonization were the nose and throat (Table 1) , and 36 patients (58%) had gastrointestinal MRSA colonization (positive rectal cultures). However, no patients were found to have MRSA colonization by rectal culture only. In addition, 6 (26%) of 23 women had vaginal colonization. Seventeen (27%) of the patients presented with MRSA infection (Table 1) . A minority of patients had community-acquired MRSA colonization (Table 1) . Three isolates (5%) were positive for the community-acquired MRSA marker Panton-Valentine leukocidin, whereas the gene for toxic-shock syndrome toxin 1 was found in 3 other isolates. No isolate was positive for the exfoliative toxin gene. Overall, 54 of the patients (87%) were successfully decolonized (intent-to-treat analysis). Of the 8 patients with decolonization failure, 7 did not complete the decolonization treatment course according to the protocol, because of noncompliance (3 patients) or sociomedical reasons (4 patients). The patient for whom decolonization failed despite completion of the decolonization treatment course was a young man who had been transferred to our hospital from Brazil after a car accident. After treatment of an open fracture, he developed a chronic osteomyelitis caused by multidrug-resistant Pseudomonas aeruginosa and was found to be colonized with MRSA (MRSA was not found in the bone biopsy). Treatment of osteomyelitis failed, as did decolonization after completion of 6 decolonization treatment cycles. It was therefore decided to postpone further decolonization treatment until the osteomyelitis was under control. Treatment was successful in 51 (98%) of 52 (on-treatment analysis) of the patients who completed the full decolonization treatment cycle.
For 29 (46.7%) of 62 of the patients, MRSA eradication was achieved after 1 decolonization course (Figure 2) . A minority of patients (10 [16%]) underwent more than 3 decolonization courses. Patients with MRSA colonization at a single body site required significantly fewer decolonization courses for successful eradication than did those with colonization at multiple sites (eradication rate after 1 course, 76.9% of patients with 1 site colonized and 38.7% of patients with multiple sites colonized; P = .004) (Figure 2 ). MRSA colonization persisted longer in patients with throat colonization than in patients with colonization of other sites (Figure 3) . Decolonization was not successful in 23.5% of MRSA-infected patients, compared with 8.8% of colonized patients. Decolonization in patients with MRSA spa type t041 was more difficult to achieve than was decolonization in patients with other spa types (eradication rate after 1 course, 26.6% and 51.2%, respectively); however, the difference was not statistically significant (P = .20). After successful decolonization, recolonization with MRSA occurred in 10 patients, after a mean interval of 240 days (range, 24-536 days). The recolonization isolate from 1 patient was not available for typing. One patient was colonized with a new MRSA type, confirmed by the presence of a new spa type (t008 and t032). In 8 patients, the recolonization strains were indistinguishable from the previous isolates by PFGE, a finding possibly indicating decolonization failure or recolonization by the identical strain. However, the long-term eradication rate was still 72.6%, under the assumption that all patients mentioned above are considered to have decolonization failure. A mean of 4 control screening cultures were available after successful decolonization during a median follow-up period of 34 months (range, 0-72 months).
Mupirocin resistance was rare (Table 2 ). There was no mupirocin resistance observed in strains of MRSA from patients who were recolonized.
Rates of susceptibility to rifampin, fusidic acid, and cotrimoxazole were 92%, 83%, and 89%, respectively. No glycopeptideresistant MRSA strains were found. Of 62 isolates, 56 were available for spa typing. Of these, 40 (71.4%) belonged to 5 widely distributed epidemic spa types that are circulating throughout Europe (Table 1) .
D I S C U S S I O N
Eradication of MRSA carriage may reduce the risk of infection in MRSA-colonized patients and prevent MRSA crosstransmission to other individuals. However, the efficacy of MRSA decolonization treatment still remains controversial. 8, 9 Our study demonstrates that MRSA decolonization with a combination of topical and systemic antimicrobial agents is highly effective for patients completing the full decolonization treatment course. Our decolonization success rate of 87% is higher than most rates that have been reported elsewhere in the literature. 811 None of the previous studies defined decolonization success as rigorously as ours: at least 6 body sites, some of them almost never screened in published studies (eg, the vagina), had to test negative by use of state-of-the-art selective enrichment broth methods. 12 There are several possible reasons for the high efficacy of our MRSA decolonization strategy. First, several other trials evaluated the efficacy of MRSA decol- 24 In pediatric patients with cystic fibrosis, a 3-step protocol with topical mupirocin, chlorhexidine for washing, and a 5-day course of rifampin and fusidic acid has been evaluated; MRSA eradication was achieved in 16 (94%) of 17 patients-8 (47%) after 1 decolonization course and 8 (47%) after 2 or 3 decolonization courses. 25 Maraha et al. 26 found the rate of MRSA elimination to be 100% after a mean of 1.6 courses of treatment with enteral vancomycin and topical antimicrobials during an outbreak; decolonization was achieved after 1 course in 69% of patients.
Second, decolonization failure has been reported in patients colonized with MRSA strains with low-level mupirocin resistance. 23 In our study, the rate of low-level mupirocin resistance was low. Of 3 patients colonized with strains with low-level mupirocin resistance, 2 did not undergo decolonization because of noncompliance, and 1 patient was successfully decolonized. The only patient colonized with a strain with high-level mupirocin resistance did not complete decolonization because of noncompliance. In addition, decolonization failure or MRSA recolonization during follow-up was not associated with mupirocin resistance.
Third, previous studies have revealed that the gastrointestinal tract is an important MRSA reservoir in colonized patients. 27, 28 In our study, more than half of the patients had MRSA colonization of the gastrointestinal tract, as indicated by positive rectal cultures. Decolonization procedures using topical antimicrobial agents focus on eradication of MRSA on nares, skin, and, less frequently, the throat. However, treatment is not targeted at gastrointestinal colonization, facilitating recolonization of other body sites. Silvestri et al. 29 found eradication of MRSA gut carriage by treatment with enteral vancomycin to be effective in the reduction of the rate of MRSA colonization and infection in an outbreak among patients receiving mechanical ventilation in intensive care units. Maraha et al. 26 reported a 100% success rate for MRSA decolonization with enteral vancomycin and topical antimicrobial treatment during an outbreak in a urological unit. In our study, elimination of gut carriage could have minimized the rate of decolonization failure and the risk of recolonization in our population.
Recent studies have shown that the throat is an important site for MRSA colonization that can persist for years. 12, 30 Our data suggest that throat colonization is more difficult to eradicate than is colonization of other sites. One possible reason for this could be the insufficient levels of antiseptics that are achieved in the crypts of the tonsils with topical treatment. In addition, S. aureus can be internalized by human cells and can survive intracellularly. 31 Systemic antibiotics, especially rifampin and cotrimoxazole, may achieve better tissue and intracellular levels, 32 leading to higher MRSA eradication rates. However, this has to be confirmed in further studies.
Countries such as The Netherlands also routinely decolonize MRSA carriers. They report low prevalences of MRSA carriage, similar to those observed in our institution. We speculate that routine decolonization, which has been underestimated in the past as a strategy to control the spread of MRSA, may contribute to the low prevalence.
Our study has several limitations. It was not a randomized controlled trial; therefore, there was no appropriate control group. The study population consisted of a selected group of patients, 34% of whom did not meet inclusion criteria. This could have led to overestimation of the decolonization success. However, 27% of the patients were not only colonized but also infected with MRSA, which added obstacles to successful decolonization. The number of cases was small because of a low local MRSA prevalence. In fact, Switzerland has a very low rate of antibiotic use, 33 leading to low selection pressure and potentially allowing MRSA to escape detection by screening culture. Finally, although the study design was prospective, with standardized protocols, PCR for the pvl and tsst genes and the additional method of spa typing were introduced during the study period. However, PFGE was used throughout the study.
In conclusion, this standardized regimen including a combination of topical and systemic antimicrobial agents was highly effective for MRSA decolonization in colonized and infected individuals. The majority of patients were successfully decolonized with 2 or 3 decolonization courses. Decolonization of patients with throat carriage seems to be more difficult to achieve than decolonization of patients with carriage at other sites, and systemic antibiotics may be necessary in the treatment of patients whose conditions do not respond to topical therapy. Specific treatment of gastrointestinal and urogenital MRSA reservoirs may improve the rate of successful decolonization. However, the evolution of other antibiotic-resistant organisms, such as vancomycin-resistant enterococci, needs to be carefully monitored.
